alferminogene tadenovec

AXP000151.1 · Viral vector gene therapy

Platform
adenovirus (Ad5, non-replicating, FGF-4)
Targets
FGF4
Originator
Berlex / Schering AG
Sponsor
Angionetics (Gene Biotherapeutics)

Names

NameTypeSource
alferminogene tadenovecpreferred name, INNcurator, ncit
Generxbrandpress
Ad5FGF-4codepress

Virus

Role
In vivo gene transfer
Family
Adenoviridae
Virus
human adenovirus 5 (NCBI Taxonomy 28285)
Strain
Ad5
Replication
non replicating
Modifications
non-replicating Ad5 encoding human fibroblast growth factor 4
Transgenes
FGF4
Route
intra arterial
Source
evidence

Cross-references

NCI Thesaurus
C184852
FDA UNII
79EDH25YRK

Approvals

No regulatory approval recorded.

Clinical trials (4)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT02928094Ad5FGF-4 In Patients With Refractory Angina Due to Myocardial IschemiaUnknownPhase 32023-01-012024-03-01160Angina, Stable
NCT01550614Efficacy and Safety of Ad5FGF-4 for Myocardial Ischemia in Patients With Stable Angina Due to Coronary Artery DiseaseTerminatedPhase 32012-032016-0511Angina, Stable
NCT00438867Angiogenesis in Women With Angina Pectoris Who Are Not Candidates for RevascularizationUnknownPhase 32007-052009-11300Angina Pectoris
NCT00346437Efficacy and Safety of Intracoronary Ad5FGF-4 in Patients With Stable Angina (AGENT-3)CompletedPhase 2/32001-102005-01416Angina Pectoris
Unconfirmed matches (1)

Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditionsMatched by
NCT00185263Safety and Efficacy of Intracoronary Ad5FGF-4 in Patients With Stable AnginaUnknownPhase 2/32002-032005-01116Stable Anginaname in title: Ad5FGF-4

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 23957658Evaluation of ASPIRE trial: a Phase III pivotal registration trial, using intracoronary administration of Generx (Ad5FGF4) to treat patients with recurrent angina pectoris.Expert opinion on biological therapy2013cited by trial NCT01550614
PMID 17825712Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials.Journal of the American College of Cardiology2007cited by trial NCT00346437
PMID 16218781Arteriogenic gene therapy in patients with unreconstructable critical limb ischemia: a randomized, placebo-controlled clinical trial of adenovirus 5-delivered fibroblast growth factor-4.Human gene therapy2005name in abstract: Ad5FGF-4
PMID 14563572A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina.Journal of the American College of Cardiology2003name in title: Ad5FGF-4

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 18379964Alferminogene tadenovec, an angiogenic FGF4 gene therapy for coronary artery disease.IDrugs : the investigational drugs journal2008name in title: alferminogene tadenovec
PMID 17722485Development of parallel line analysis criteria for recombinant adenovirus potency assay and definition of a unit of potency.PDA journal of pharmaceutical science and technology2007name in abstract: Ad5FGF-4
PMID 15958178A potency assay for a replication incompetent adenovirus type 5 carrying a human fgf-4 gene.Analytical biochemistry2005name in abstract: Ad5FGF-4
PMID 14988742Gateways to clinical trials.Methods and findings in experimental and clinical pharmacology2004name in abstract: Ad5FGF-4
PMID 15180588Clinical use of intracoronary gene transfer of fibroblast growth factor for coronary artery disease.Current gene therapy2004name in abstract: Ad5FGF-4
PMID 12894451Gene therapy for coronary artery disease: preclinical and initial clinical results with intracoronary administration of Ad5FGF-4.Ernst Schering Research Foundation workshop2003name in title: Ad5FGF-4
PMID 14615023Angiogenic gene therapy with adenovirus 5 fibroblast growth factor-4 (Ad5FGF-4): a new option for the treatment of coronary artery disease.The American journal of cardiology2003name in title: Ad5FGF-4
PMID 11909005FGF-4 gene therapy GENERX--Collateral Therapeutics.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2002name in title: Generx
PMID 12031124A single short stretch of homology between adenoviral vector and packaging cell line can give rise to cytopathic effect-inducing, helper-dependent E1-positive particles.Human gene therapy2002name in abstract: Ad5FGF-4

NIH grants

ProjectTitleOrganisationPIYearsLinked by
R43NS061455Biomarker panel to differentiate stroke from stroke mimicPREDICTION SCIENCES, LLCMAN, ALBERT K2008–2008name in abstract: Generx
R44CA117001GeneRx - colorectal cancer recurrence predictionPREDICTION SCIENCES, LLCLINKE, STEVEN P2007–2008name in title: Generx
R43CA117001GeneRx - colorectal cancer recurrence predictionPREDICTION SCIENCES, LLCLINKE, STEVEN P2005–2005name in title: Generx
R44HL065791Improved Plasmid/Liposome Administration to the LungsGENERX+, INC.SANDERS, JONATHAN R2002–2003name in abstract: Generx
R43MH066671Pharmacogenetic Prediction of Paroxetine ResponsePREDICTION SCIENCES, LLCHEROLD, CHRISTOPHER D2002–2002name in abstract: Generx
R41DK059732Alpha-1 Antitrypsin Gene Therapy for Cystic FibrosisGENERX+, INC.BRIGHAM, KENNETH L2001–2001name in abstract: Generx
R43HL065791IMPROVED PLASMID/LIPOSOME ADMINISTRATION TO THE LUNGSGENERX+, INC.SANDERS, JONATHAN R2000–2000name in abstract: Generx

Notes

Generx: single intracoronary infusion of a non-replicating Ad5 carrying human FGF-4 to induce collateral vessel growth in refractory angina due to coronary artery disease. Reached phase 3 (AFFIRM / AWARE); FDA cleared a further US phase 3 study. Not a cancer product.

How to cite

alferminogene tadenovec (AXP000151.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000151.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.